Medical Pharmacology Practice Questions: Cholinergic Drugs

Location(s) of cholinergic synaptic sites:
1. neuromuscular junction
2. autonomic effector sites innervated by post-ganglionic sympathetic fibers
3. some CNS synapses
4. A & C
5. B & C
Factors that limit CNS effects of systemic acetylcholine: administration:
1. poor CNS penetration
2. inactivation by plasma butrylcholinesterase
3. both
4. neither
Localization of muscarinic cholinergic receptors:
1. postganglionic parasympathetic effector sites
2. autonomic ganglia cells
3. adrenal medulla
4. A & C
5. A, B & C
Cholinergic receptor type primarily localized at skeletal muscle neuromuscular junctions:
1. muscarinic
2. nicotinic
Highly sensitive to the action of acetylcholinesterase:
1. carbachol
2. bethanechol (Urecholine)
3. acetylcholine
4. A & C
5. A,B, & C
Muscarinic receptor subtype primarily associated with the heart:
1. M1
2. M2
3. M3
4. M4
Effective antagonist at neuromuscular junction receptors;
1. atropine
2. tubocurarine
Most likely to be effective in blocking all ganglionic neurotransmission:
1. tubocurarine
2. mecamylamine (Inversine)
3. atropine
4. all of the above
Cardiac muscarinic Type M2-receptor mediated action(s):
1. increased phase 4 depolarization rate
2. increased AV nodal conduction velocity
3. Decreased atrial and ventricular contractility
4. all the above
Ligand-gated ion channels:
1. nicotinic
2. muscarinic
3. both
4. neither
Tends to cause fast responses:
1. nicotinic
2. muscarinic
Agonist effects blocked by tubocurarine:
1. muscarinic receptors
2. nicotinic receptors
Indirect-acting cholinomimetic:
1. atropine
2. edrophonium (Tensilon)
3. carbachol
4. acetylcholine
5. ephedrine